GLP-1 & Metabolic Psychiatry: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• WorkshopObesity and Eating Disorders

  Kamryn Eddy · Laura Holsen · Ashley Dunford · Esther Dechant · Jennifer Thomas · Evelyna Kambanis · Kendra R. Becker

  Ticketed evening session covering assessment and treatment of obesity and the spectrum of eating disorders.

  Eating Disorders

• WorkshopNutritional, Lifestyle, and Metabolic Psychiatry

  Uma Naidoo · David Mischoulon · Beth Frates · Ramaswamy Viswanathan · Errol R. Norwitz · Kimberley A. Parks

  Ticketed evening session on how nutrition, lifestyle change, and metabolic health intersect with psychiatric treatment.

  Lifestyle & Integrative Psychiatry

• LecturePsychopharmacology of Obesity with Comorbid Eating Disorders

  Esther Dechant

  Medication approaches for patients who have obesity together with an eating disorder.

  Eating DisordersMedical Comorbidity & C-L Psychiatry

• WorkshopNutritional, Lifestyle, and Metabolic Psychiatry Program

  Uma Naidoo · David Mischoulon · Beth Frates · Ramaswamy Viswanathan · Errol R. Norwitz · Kimberley A. Parks

  Ticketed Thursday evening program on nutrition, lifestyle and metabolic approaches in psychiatry.

  Lifestyle & Integrative Psychiatry

• PanelPanel Discussion: Dual Management of Obesity and Eating Disorders

  Kamryn Eddy · Laura Holsen · Ashley Dunford · Esther Dechant

  Panel discussion on managing obesity and eating disorders together in clinical care.

  Eating Disorders

See all 8 glp-1 & metabolic psychiatry sessions at this meeting →

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• LectureNext-Generation Therapies for Obesity and Associated Food-Related Aggression in Intellectual and Developmental Disabilities

  Ernest Pedapati

  Covers emerging treatment options for obesity and food-related aggression in people with intellectual and developmental disabilities.

  Autism & Neurodevelopmental DisordersChild & Adolescent

• LectureEvidence-Based Strategies to Screen and Manage Endocrine and Metabolic Complications

  Sadiq Naveed

  Reviews screening and management of endocrine and metabolic complications of psychotropic medications in children and adolescents.

  Antipsychotic PrescribingChild & Adolescent

• SymposiumClinical Pathways for Antipsychotic-Associated Weight Gain in Youth: GLP-1–Based Treatment, Multimodal Care, and Behavioral Interventions

  Musa Yilanli · Eileen A. Chaves · Zhanna Elberg · Perihan Esra Guvenek-Cokol · Amy L. Christison · Hiba Salhah

  Clinical session laying out care pathways for antipsychotic-associated weight gain in youth, including where GLP-1 receptor agonists, multimodal care, and behavioral interventions fit.

  Antipsychotic PrescribingChild & Adolescent

• SymposiumGLP-1 Receptor Agonists and Eating Disorders: Emerging Evidence, Risks, and Clinical Considerations

  Felicia G. Gallucci · Jennifer L. Derenne · Aisa M. Moreno-Megui · Alexandra N. Coppa · Jessica D. Leuchter

  Session on the intersection of GLP-1 receptor agonists and eating disorders in youth — emerging evidence, risks of misuse, and clinical considerations for prescribers.

  Child & AdolescentEating Disorders

• PosterPharmacovigilance Analysis of Psychiatric Adverse Events Associated With Semaglutide and Liraglutide

  Qiyang Pan · Chenyu Sun

  Pharmacovigilance poster analyzing reported psychiatric adverse events linked to semaglutide and liraglutide.

  Drug Interactions & Safety

See all 27 glp-1 & metabolic psychiatry sessions at this meeting →

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• LectureGLP-1 Receptor Agonist in Psychiatric Care: Navigating Scope and Liability

  Natasha Carew

  Looks at the growing use of GLP-1 agonists in psychiatric settings and the scope-of-practice, regulatory, and liability questions they raise.

  Practice, Policy & Workforce

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• SymposiumFrom Metabolism to Addictions: Repurposing GLP-1 Therapies for Alcohol and Other Substance Use Disorders

  Lorenzo Leggio · Joji Suzuki · Luba Yammine · Manish Jha

  Surveys preclinical and emerging clinical evidence for GLP-1 receptor agonists as candidate treatments for alcohol and other substance use disorders.

  Alcohol Use DisorderSubstance Use Disorders

• SymposiumSymposium I - From Metabolism to Addictions: Repurposing GLP-1 Therapies for Alcohol and Other Substance Use Disorders

  Lorenzo Leggio · Joji Suzuki · Luba Yammine · Manish Jha

  Reviews preclinical, observational and early randomized trial evidence on using GLP-1 receptor agonists to treat alcohol and other substance use disorders, including psychiatric safety.

  Alcohol Use DisorderSubstance Use Disorders

• PosterBeyond Weight Loss: GLP- 1 Receptor Agonists for Alcohol Use Disorder- A Systematic Review and Meta-Analysis

  Ramita Goel

  Systematic review and meta-analysis of GLP-1 agonists for AUD.

  Alcohol Use Disorder

• PosterExpanding the Therapeutic Landscape of Alcohol Use Disorder: Brenipatide (Dual GIP/GLP-1 Receptor Agonist) Clinical Trials

  Marc Fishman

  Overview of clinical trials of a dual GIP/GLP-1 agonist for AUD.

  Alcohol Use DisorderDrug Pipeline & Clinical Trials

• PosterGLP-1 Receptor Agonists in Alcohol Use Disorder: Outcome-Domain Synthesis With Exploratory Aggregate-Data Pooling of Randomized Trials

  Mahnoor Waqar

  Synthesis and pooling of randomized trials of GLP-1 agonists in AUD.

  Alcohol Use Disorder

NPA 32nd Annual Psychopharmacology Update 2027

February 10–13, 2027 · Las Vegas, NV

• LectureUsing GLP-1s in Psychiatry

  Roger S. McIntyre

  Where GLP-1 receptor agonists fit in psychiatric practice, from antipsychotic-associated weight gain to emerging behavioral indications.

  Antipsychotic Prescribing

Substance Use Disorders: A Comprehensive Review and Update 2027

February 15–17, 2027 · Lake Buena Vista, FL

• LectureGLPs

  Megan Hudson

  GLP-1 agents in the context of substance use treatment.

  Substance Use Disorders

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• SessionRS – Regulatory Spotlight Session – Metabolic risks of psychiatric medications: improving clinical safety through regulatory, industry, and academic insights

  Margaret Hahn · Vikas Mohan Sharma · Katarina Vucic

  Academic, industry, and regulator perspectives on managing metabolic risks of psychotropic medications.

  Antipsychotic PrescribingDrug Interactions & Safety

WCP 2026 — 26th World Congress of Psychiatry

September 23–26, 2026 · Stockholm, Sweden

• PlenaryPlenary Session 07: Addiction Science as a Window into Brain Function

  Nora Volkow

  Nora Volkow's plenary on addiction neuroscience; the speakers page frames her talk around GLP-1 agonists and balancing neuro-metabolic opportunities with clinical realities.

  Neuroscience & MechanismsSubstance Use Disorders

Medical Psychiatry: Comprehensive Update Conference 2026

September 17–20, 2026 · Online

• KeynoteKEYNOTE: GLP-1s & Management of Substance Use Disorders

  Joji Suzuki

  Emerging evidence on GLP-1 receptor agonists as potential treatments for addiction.

  Substance Use Disorders

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• CourseAdvanced Psychopharmacology Intensive: Emerging Neurobiologic Targets and Metabolic Pathways Reshaping Psychiatric Treatment

  Brittany Albright · Rakesh Jain · Gregory Mattingly · David Plante

  Half-day ticketed intensive built around four expert-led modules on treatment mechanisms moving beyond monoamines: orexin-based agents, glutamate/dopamine circuit approaches, muscarinic receptor modulation, and GLP-1/bioenergetic pathways.

  Muscarinic & Novel AntipsychoticsNeuroscience & MechanismsDrug Pipeline & Clinical Trials

• CourseIntegrative Psychiatry Intensive: Systems-Level Biology and Lifestyle Factors Transforming Psychiatric Practice

  James Greenblatt · Ashley Mason · Charles Raison

  Half-day ticketed intensive covering four integrative domains — temperature-based interventions, rapid sleep-optimization strategies, nutritional psychiatry, and metabolic regulation of brain function — framed as complements to standard psychopharmacology.

  Lifestyle & Integrative PsychiatrySleep & Insomnia

• SymposiumMind & Metabolic Matters: Practical Guidance on Prescribing GLP-1s in Psychiatry

  Brittany Albright · Jonathan M. Meyer

  Clinic-ready framework for GLP-1 and dual-incretin use in psychiatric patients: selection, titration, adverse-effect management, and psychiatric considerations including eating disorder risk, mood monitoring, and craving implications.

  Drug Interactions & SafetyEating Disorders

• DebateWhen Standard Treatment Isn't Enough: Complex Schizophrenia Cases and Clinical Decision-Making

  Leslie Citrome · Erin Crown · Brooke Kempf

  Panel works through challenging schizophrenia cases involving treatment resistance and functional decline, covering sequencing, clozapine timing, augmentation, and metabolic and sedation trade-offs.

  Antipsychotic PrescribingClozapineSchizophrenia & Psychosis